News Germany will reimburse haemophilia gene therapy Hemgenix Germany has agreed to reimburse CSL Behring's haemophilia B gene therapy Hemgenix with a 'unique' outcomes-based payment model.
News NHS should pay for medicines based on outcomes, argues Novar... A new report from the Social Market Foundation think tank argues that the UK’s National Health Service should switch to paying for medicines based on patient outcomes.
Oncology On looking to a future multiomics approach for CDx, with Jan... The pharmaphorum podcast caught up with Jane Li, VP and general manager for companion diagnostics at Thermo Fisher Scientific, following ESMO 2026.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.